Insights

Why BioNTech Stock Climbed Today

What happened
Shares of BioNTech (NASDAQ: BNTX) rose on Monday, following the release of the biotechnology company’s first-quarter financial results. As of 2 p.m. ET, BioNTech’s stock price was up more than 3% after rising as much as 7.3% earlier in the day.
So what
BioNTech’s revenue surged 211% year over year to 6.4 billion euros ($6.7 billion), driven by sales of the company’s COVID-19 vaccine. The German biotech shares the proceeds from the drug with its pharmaceutical partner Pfizer in most markets across the world.
BioNTech’s net profit, in turn, soared 228% to 3.7 billion euros ($3.9 billion), or roughly $15.04 per share. That was well above analysts’ estimates, which had called for per-share profits of approximately $9.71.
Image source: Getty Images.

“We believe the global deployment of our vaccine has likely saved millions of lives and had a significant impact on humanity,” CFO Jens Holstein said in a press release. “As a result of an increased order volume initially placed in late 2021 following the then-emerging Omicron variant, we began the year 2022 with strong revenues and earnings.”
Now what
The strong start to the year has BioNTech on track to achieve its full-year financial forecast. Management expects the company to generate vaccine-related revenue of 13 billion to 17 billion euros ($13.7 billion to $18 billion) in 2022.
BioNTech intends to use a significant portion of the profits it earns from its vaccine to fund its expansive research and development program. It has 20 oncology-focused clinical trials currently underway.
BioNTech also plans to pay a special cash dividend of 2 euros ($2.11) per share and buy back as much as $1.5 billion worth of its stock over the next two years.
Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. –

What happened

Shares of BioNTech (NASDAQ: BNTX) rose on Monday, following the release of the biotechnology company’s first-quarter financial results. As of 2 p.m. ET, BioNTech’s stock price was up more than 3% after rising as much as 7.3% earlier in the day.

So what

BioNTech’s revenue surged 211% year over year to 6.4 billion euros ($6.7 billion), driven by sales of the company’s COVID-19 vaccine. The German biotech shares the proceeds from the drug with its pharmaceutical partner Pfizer in most markets across the world.

BioNTech’s net profit, in turn, soared 228% to 3.7 billion euros ($3.9 billion), or roughly $15.04 per share. That was well above analysts’ estimates, which had called for per-share profits of approximately $9.71.

Image source: Getty Images.

“We believe the global deployment of our vaccine has likely saved millions of lives and had a significant impact on humanity,” CFO Jens Holstein said in a press release. “As a result of an increased order volume initially placed in late 2021 following the then-emerging Omicron variant, we began the year 2022 with strong revenues and earnings.”

Now what

The strong start to the year has BioNTech on track to achieve its full-year financial forecast. Management expects the company to generate vaccine-related revenue of 13 billion to 17 billion euros ($13.7 billion to $18 billion) in 2022.

BioNTech intends to use a significant portion of the profits it earns from its vaccine to fund its expansive research and development program. It has 20 oncology-focused clinical trials currently underway.

BioNTech also plans to pay a special cash dividend of 2 euros ($2.11) per share and buy back as much as $1.5 billion worth of its stock over the next two years.

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

  • This field is for validation purposes and should be left unchanged.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US & HK* Trades. Click Here!